Summary
Over 60 million people in Europe live with cardiovascular diseases (CVDs). Those affected experience a lower quality of life and poor wellbeing. Left untreated, CVDs tend to progress along a ‘CVD continuum’; people start with risk factors such as high blood pressure or diabetes, and then develop increasingly severe problems such as heart attacks or strokes. At the end of the continuum lies full-blown heart failure. All too often, care is reactive, with patients only starting treatment when they have already travelled a long way down the CVD continuum.
As the name suggests, the aim of EXIT-CVD is to help patients exit the CVD continuum. They will do this by pinpointing strategic exit points along the continuum and identifying the tests and treatments that will stop CVDs in their tracks and even reverse them.
As a first step, the team will integrate clinical, imaging, genetic, and lifestyle data from around 700 000 patients from different cohorts. They will then use artificial intelligence (AI) / machine learning (ML) models to analyse the data and identify the factors that determine which patients’ CVD is at greatest risk of progressing. This will allow the project to identify the most vulnerable patients and the exit points where interventions will make the biggest difference.
Next, the team will validate novel diagnostics and monitoring tools, including advanced imaging technologies and wearable devices. They will also test targeted interventions at key exit points. The interventions, as well as the diagnostics and monitoring tools, will be tested in clinical studies. The studies will cover the entire CVD continuum, from early detection through intermediate stratification to late stage recovery.
In parallel, the project will work hand in hand with patients and health technology assessment (HTA) bodies to ensure innovations are not only effective, but feasible, acceptable, and scalable across European health systems. The project adopts an ‘equity-by-design’ approach to proactively address gender, socio-economic and other disparities in the care of people with CVDs.
In the long term, EXIT-CVD’s outputs will help to transform the lives of people with CVDs by stopping or even reversing their progress along the CVD continuum.
Participants
Show participants on mapCOCIR
- Ge Precision Healthcare Llc, Wilmington, United States
- Huawei Technologies Oy (Finland) Co LTD, Helsinki, Finland
- Huawei Telekomünikasyon Dis Ticaret Limited Sirketi, İstanbul, Türkiye
- Philips Electronics Nederland BV, Eindhoven, Netherlands
- Philips GMBH, Hamburg, Germany
- Philips Nederland BV, Eindhoven, Netherlands
- Siemens Healthineers AG, Forchheim, Germany
EFPIA including Vaccines Europe
- Astrazeneca AB, Sodertaelje, Sweden
- Bgp Products Operations GMBH, Steinhausen, Switzerland
- Novartis Pharma B.V., Amsterdam, Netherlands
- Sanofi-Aventis Deutschland GMBH, Frankfurt Am Main, Germany
MedTech Europe
- Abiomed Europe GMBH, Aachen, Germany
- Cordys Analytics B.V., Utrecht, NetherlandsSME
- Iqvia Solutions B.V., Amsterdam, Netherlands
- Johnson & Johnson Medical B.V., Amersfoort, NetherlandsThird-party
- Medtronic Iberica SA, Madrid, Spain
- Zoll Cms GMBH, Koln, Germany
Contributing partners
- Circle Cardiovascular Imaging Inc., Calgary, Canada
- Cogstack Limited, Hadlow, United KingdomSME
- Corbotics B.V., Delft, NetherlandsSME
- Heartbeam Inc, Santa Clara, United StatesSME
- Repairon GMBH, Gottingen, GermanySME
- Xvivo Perfusion Aktiebolag, Goteborg, SwedenSME
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
- Bridg Ou, Tallin, Estonia
- Cardio Med SRL, Targu Mures, Romania
- Megi Health d.o.o., Zagreb, Croatia
- Onsentia Limited, Hadlow Kent, United Kingdom
Universities, research organisations, public bodies, non-profit groups
- Academisch Ziekenhuis Groningen, Groningen, Netherlands
- Ente Ospedaliero Cantonale, Bellinzona, Switzerland
- Fundacio De Gestio Sanitaria De L'Hospital De La Santa Creu I Sant Pau, Barcelona, Spain
- Katholieke Universiteit Leuven, Leuven, Belgium
- King'S College London, London, United Kingdom
- Klinikum Der Universitaet Zu Koeln, Koeln, Germany
- London School Of Economics And Political Science, London, United Kingdom
- Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego - Panstwowy Instytut Badawczy, Warszawa, Poland
- Politecnico Di Milano, Milano, Italy
- Technische Universiteit Eindhoven, Eindhoven, Netherlands
- Universita Degli Studi Di Pavia, Pavia, Italy
- Universitair Medisch Centrum Utrecht, Utrecht, Netherlands
- Varsinais-Suomen Hyvinvointialue, Turku, Finland
Patient organisations
- Societe Europeenne De Cardiologie, Biot, France
- Stichting VrouwenHart, Leidschendam, Netherlands
Other companies
- Centro Cardiologico Monzino, Milano, Italy
| Participants | |
|---|---|
| Name | EU funding in € |
| Academisch Ziekenhuis Groningen | 2 601 957 |
| Bridg Ou | 188 193 |
| Cardio Med SRL | 274 560 |
| Centro Cardiologico Monzino | 726 198 |
| Cogstack Limited | 46 500 |
| Corbotics B.V. | 260 000 |
| Cordys Analytics B.V. | 254 800 |
| Ente Ospedaliero Cantonale | 92 633 |
| Fundacio De Gestio Sanitaria De L'Hospital De La Santa Creu I Sant Pau | 425 760 |
| Iqvia Solutions B.V. | 637 000 |
| Katholieke Universiteit Leuven | 171 935 |
| King'S College London | 178 208 |
| Klinikum Der Universitaet Zu Koeln | 75 000 |
| London School Of Economics And Political Science | 556 000 |
| Medtronic Iberica SA | 1 089 900 |
| Megi Health d.o.o. | 46 500 |
| Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego - Panstwowy Instytut Badawczy | 274 560 |
| Onsentia Limited | 88 271 |
| Philips Electronics Nederland BV | 1 076 531 |
| Philips GMBH | 1 153 875 |
| Philips Nederland BV | 289 000 |
| Politecnico Di Milano | 71 385 |
| Siemens Healthineers AG | 659 850 |
| Societe Europeenne De Cardiologie | 359 000 |
| Stichting VrouwenHart | 29 175 |
| Technische Universiteit Eindhoven | 75 286 |
| Universita Degli Studi Di Pavia | 47 019 |
| Universitair Medisch Centrum Utrecht | 2 100 678 |
| Varsinais-Suomen Hyvinvointialue | 270 675 |
| Xvivo Perfusion Aktiebolag | 41 730 |
| Zoll Cms GMBH | 1 036 655 |
| Total Cost | 15 198 834 |